Yuhan Corporation to pay $325M to in-license preclinical HER2 candidate

31 May 2023
endpts.com
AACRPROTACs
Yuhan Corporation said Tuesday that it is paying up to $325 million to fellow South Korean biotech J INTS Bio to license an oral non-small cell lung cancer drug. The deal is for JIN-A04, a preclinical oral tyrosine kinase inhibitor targeting NSCLC with HER2 exon 20 mutations. J INTS Bio said back in February that preclinical data on the molecule would be presented at the American Association for Cancer Research’s annual meeting in Orlando, saying that the molecule “showed potent efficacy against HER2 Exon20 insertion mutant NSCLC cell lines, and in-vivo mouse models using HER2 Exon20 insertion mutant cell lines significant tumor regression was demonstrated.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.